Agenus Inc. (AGEN)

Over the past six months, Agenus's stock price has experienced volatility. In March 2026, Agenus reported its Q4 and full-year 2025 financial results, triggered the first $20 million contingent payment under its collaboration with Zydus Lifesciences, and was downgraded by Wall Street Zen from a "buy" to a "hold" rating. B.Riley reiterated a "Buy" rating and an $8.00 price target on Agenus Inc. The company's Q3 FY 2025 results showed a swing to profit with a net income of $63.9 million and EPS of $2.00. In January 2026, Agenus announced the closing of its strategic collaboration with Zydus Lifesciences and appointed Garo Armen as Chief Financial Officer. In December 2025, Weiss Ratings restated a "sell (e+)" rating on Agenus. In November 2025, analysts made a "huge upgrade" to their Agenus Inc. revenue forecasts. In October 2025, Agenus reported 39% of patients alive at two years with BOT/BAL across multiple refractory solid tumors at ESMO 2025. The share price as of March 30, 2026, was $3.24, representing an increase of 115.28% over the previous year.

Information specifically detailing demand seasonality for Agenus, Inc.'s products and services is not readily available. Demand for its products would primarily be driven by clinical trial progress, regulatory approvals, and the prevalence of the specific cancers and infectious diseases it targets, rather than traditional seasonal patterns. The early access programs generating revenue suggest a consistent demand from patients with limited treatment options, rather than seasonal fluctuations.

Agenus, Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. The company operates within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical industries. Agenus's primary business is immuno-oncology, aiming to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. Major products and pipeline candidates include Botensilimab, Balstilimab, QS-21 Stimulon adjuvant, Retrocyte Display, and Prophage vaccines, among other pipeline candidates.

Agenus, Inc. has a global clinical operations footprint and discovers and develops immunotherapies in the United States and internationally. The company is headquartered in Lexington, Massachusetts, USA. Early access programs for botensilimab and balstilimab have expanded globally, with over 200 inquiries from more than 30 countries, and reimbursed treatment in France.

Agenus's brand reputation in the past year appears to be largely tied to the clinical progress and strategic developments of its lead immunotherapy programs, particularly botensilimab (BOT) and balstilimab (BAL). Breakthrough efficacy data for BOT/BAL, the expansion of early access programs globally, and strategic collaborations have positively impacted the company's standing. An FDA hold on the accelerated approval filing for BOT/BAL, the company's trailing twelve-month net loss, and investor sentiment can negatively affect the brand reputation.

Agenus Inc. is a publicly traded company on NASDAQ under the ticker AGEN. As of March 31, 2026, Agenus Inc. had 100 institutional owners and shareholders holding a total of 10,187,321 shares. Major institutional owners include The Vanguard Group, Inc., BlackRock, Inc., and Geode Capital Management, Llc, among others. Garo H. Armen is the largest individual shareholder. Other significant insider holders include Incyte Corp, Qvt Associates GP LLC, and Invus Public Equities LP, among others. Institutional investors collectively held approximately 35.41% of Agenus shares by April 2025. Insider ownership stood at 0.74% in April 2025.